SEC Form 4 · accession 0001193125-26-335115
4D Molecular Therapeutics, Inc. · FDMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Kirn
Officer — See Remarks · Director
Period of report
Aug 4, 2026
Accepted (ET)
Aug 5, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001650648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 4, 2026 | S | 26,842 | $10.2301 | D | 844,895 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.
- F2The transaction was executed in multiple trades in prices ranging from $10.07 to $10.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.